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Abstract 1 
Beneficial microbes, such as lactobacilli establish a symbiosis with the host and confer health-associated 2 
effects, by limiting the growth of indigenous pathogens and challenging microbes introduced by altered foods. 3 
Nevertheless, there is scarce information on the effects of beneficial microbes on the virulence properties of 4 
bacterial species associated with oral diseases, such as periodontitis. Aggregatibacter actinomycetemcomitans, 5 
is a gram-negative species highly implicated in the etiology of localized aggressive periodontitis. The 6 
objective of this study was to investigate the effect of lactobacilli on the expression of the two major virulence 7 
factors of A. actinomycetemcomitans. Lactobacillus salivarius and L. gasseri were selected as beneficial 8 
species. The gene expressions of leukotoxin (LtxA) and cytolethal distending toxin (CdtB) by A. 9 
actinomycetemcomitans were analyzed in response to challenge by lactobacilli cell-free supernatants. Both 10 
lactobacilli did not affect the growth, but strongly attenuated the expressions of both CdtB and LtxA, in the 11 
two A. actinomycetemcomitans strains tested. This reduction of the expression of these two exotoxins was 12 
time-dependent. These fundamental findings may indicate that lactobacilli can reduce the virulence of 13 
putative opportunistic oral pathogens and may provide insights to future therapeutic approaches for the 14 
respective diseases.  15 
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 28 
Introduction 29 
Microbial ecology has now entered the microbiome era, which is the systemic study of a microbial 30 
community as a functional entity (Chen et al. 2010). The Human Microbiome Project of the United States 31 
National Institute of Health has set the basis (Turnbaugh et al. 2007), while the Human Oral Microbiome 32 
Database (Chen et al. 2010), in particular, is investigating in further detail the specialized ecological niche of 33 
the oral cavity. The oral microbiome is one of the most studied in humans, due to the easy accessibility of 34 
bacterial samples, and the fact that some species are associated with very frequent human infections with vast 35 
socio-economical implications, such as periodontal diseases and dental caries, but also because respiratory 36 
and intestinal pathogens may access the respective systems via the oral cavity (Raghavendran et al. 2007; 37 
Kuehbacher et al. 2008). Recent evidence demonstrates that the oral cavity hosts approximately 700 prevalent 38 
bacterial taxa, with distinct subsets predominating at different habitats (Dewhirst et al. 2010). Nevertheless, 39 
not much is known about the related molecular cross talk and ecological interactions within these habitats. In 40 
this respect, a number of studies have investigated host-microbe interactions (Handfield et al. 2005; 41 
Hasegawa et al. 2007; Belibasakis et al. 2011a; Belibasakis et al. 2011b), whereas others have focused on the 42 
intimate challenge between antagonistic microbial species (Ishikawa et al. 2003). Among these microbes, 43 
some take part in disease, while others contribute to maintenance of health (Lazarevic et al. 2009). In 44 
principle, the latter could control the virulence of former, by specific strategies such as competitive exclusion 45 
or displacement. Beneficial bacteria possess different capacities aiming at limiting the growth of neighboring 46 
pathogens. For example, bacterial products like bacteriocins can exert antimicrobial activity, or even perturb 47 
the local microenvironment, by modulating the pH or O2 content, which would in turn result inhibition of 48 
certain pathogens. The disruption of a proper mutualism between commensals and pathogens within a 49 
microbial consortium can facilitate the onset of local infections and diseases. Such examples are periodontal 50 
diseases and dental caries, which are the most common oral diseases, and among the most prevalent infections 51 
in humans. While putative oral pathogens are well described, there is scarce information over the potential 52 
oral health-promoting role of indigenous commensals, such as lactobacilli that are reported as beneficial 53 
species in other ecological niches, and even used as probiotics supplements. Aggregatibacter 54 
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actinomycetemcomitans is a Gram-negative facultatively anaerobic opportunistic oral pathogen, which is 55 
highly implicated in the etiology of aggressive periodontitis (Henderson et al. 2010; Haubek 2010). The 56 
disease is characterized by rapid disease of the tooth-supporting (periodontal) tissues, and affects adolescents 57 
and young adults. The main virulence factors of A. actinomycetemcomitans are the leukotoxin and the 58 
cytolethal distending toxin (Cdt), which are protein exotoxins targeting cells of the immune system, or the 59 
periodontal tissues. The Cdt can cause growth inhibition and eventually apoptosis to virtually all eukaryotic 60 
cells, whereas the leukotoxin can selectively kill human leukocytes, or activate them to produce a strong pro-61 
inflammatory response (Fine et al. 2006). The objective of the present study was to investigate the effect of 62 
secreted lactobacilli products on the gene expression of these two virulence factors (namely LtxA and CdtB) 63 
by A. actinomycetemcomitans, in planktonic culture. The hypothesis is that the beneficial species, lactobacilli 64 
in this case, could be able to attenuate or inhibit the expression of the investigated virulence factor genes. This 65 
approach may enlighten the relationship(s) between putative periodontal pathogens and lactobacilli that can 66 
reside in the oral cavity, with known probiotic capacity for the health of the gastro-intestinal tract (GIT). It 67 
may also provide clearer insights to future adjunctive therapeutic approaches for the treatment of 68 
periodontitis. 69 
 70 
Materials and methods 71 
Microbial strains and products 72 
Aggregatibacter actinomycetemcomitans OMZ250b (Y4 clone) and OMZ295 (JP2 clone), Lactobacillus 73 
salivarius OMZ520 and L. gasseri OMZ525 were obtained from the OMZ culture collection of the Section of 74 
Oral Microbiology and Immunology, University of Zürich. Bacteria were cultured on modified Fluid 75 
Universal Medium (mFUM) (Guggenheim et al. 2001) under aerobic conditions and 10% CO2 (HeraCell 240, 76 
Heraeus, ThermoFisher Scientific, Bremen, Germany). Per Liter of distilled water, mFUM contained 10 g 77 
tryptone, 5 g yeast extract, 3 g glucose, 2 mg hemin, 1 mg menadione, 0.5 g cysteine hydrochloride, 2 g NaCl, 78 
0.5 g Na2CO3, 1 g KNO3, 0.9 g K2HPO4, 0.9 g of (NH4)2SO4, and 0.18 g MgSO4·7H20, supplemented with 67 79 
mmol Sorensen's buffer, at a pH of 7.2. A. actinomycetemcomitans strains OMZ250b (Y4 clone) and 80 
OMZ295 (JP2 clone) used in this study were cultured in mFUM supplemented with 0.3% glucose at 37 °C for 81 
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48 hours. L. salivarius OMZ520 and L. gasseri OMZ525 were also cultured in mFUM, which was instead 82 
supplemented with 0.15% glucose and 0.15% sucrose at 37 °C for 24 hours. The density of each bacterial 83 
strain in culture was quantified with a spectrophotometer at OD600 (U 2000, Hitachi, Boehringer-Mannheim, 84 
Rotkreuz, Switzerland) and CFU/ml were defined by plotting the OD against an established bacterial growth 85 
curve. After a 24 h-period of growth, the lactobacilli suspension cultures were harvested, their density was 86 
measured, and the cultures were thereafter centrifuged.  The cell pellet was discarded and the cell-free 87 
supernatants were then buffered with a 10% v/v of PBS (pH 7), filter sterilized (0.22 µm) before being used in 88 
the experimentations with A. actinomycetemcomitans, at dilutions corresponding to lactobacilli concentrations 89 
of 104 CFU/ml. 90 
 91 
Microbial interactions 92 
A. actinomycetemcomitans strain OMZ295 or OMZ250b cultures in the exponential growth phase were used, 93 
at concentration of 107 CFU/ml. These were cultured in fresh mFUM, in the presence or absence of 104 94 
CFU/ml lactobacilli cell-free supernatants (10% v/v). After 3 h and 6 h of incubation, bacterial density was 95 
quantified at OD600, and the A. actinomycetemcomitans bacterial cells in culture were harvested by 96 
centrifugation, and their total RNA content was isolated.  97 
 98 
RNA isolation and cDNA synthesis 99 
Cells were lysed with 400 µg/ml of Lysozyme in TE solution, at room temperature for 10 minutes. RNA was 100 
isolated with RNeasy mini kit and Bacteria Protect reagent (Qiagen GmbH, Hilden, Germany). RNA yield 101 
and purity was determined with a NanoDrop spectophotometer (ThermoFisher Scientific, Bremen, Germany). 102 
The isolated total RNA samples exhibited a λ260 / λ280 between 1.8 and 2.2. This was then reversed 103 
transcribed into cDNA, by using Moloney murine leukemia virus reverse-transcriptase enzyme (M-MLV RT 104 
RNase H minus) (Promega, Madison, Wi, USA). Briefly, 1 µg of total RNA was incubated with 0.5 µg/ml of 105 
Oligo(dT)15 primer (Promega) at 70 °C for 5 min and cooled on ice. A master mix was added to samples, 106 
comprising of 10 mM dNTPs, 200 units of M-MLV RT enzyme and buffer (Promega), and nuclease free 107 
water to a final volume of 25 µl. For the reverse-transcription reaction, these samples were incubated at 40 °C 108 
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for 60 min, 70 °C for 15 min and cooled down to 4 °C on a PCR apparatus (Biometra GmbH, Goettingen, 109 
Germany). The products obtained were then stored at -20 °C until further analysis by qPCR, for relative 110 
quantification of gene expression.  111 
 112 
Quantitative real time polymerase chain reaction (qPCR) 113 
Gene expressions of CdtB subunit of Cdt, LtxA subunit for leukotoxin and GlyA (glycine/serine 114 
hydroxymethyl transferase A) for the endogenous control, were analyzed using an ABI Prism7000 Sequence 115 
Detection System (Applied Biosystems, Foster City, Ca, USA), and coupled with SYBR Green Master Mix 116 
(Applied Biosystems). The CdtB gene oligonucleotide primers were designed using Primers Express 3.0 117 
software (Applied Biosystem) and the sequences were: forward: 5’-GGGCAAACCGAGTGAACTTA-3’, and 118 
reverse: 5’-CTCGTCTTTCCGGTGATGAT-3’. Primers sequences for LtxA and GlyA endogenous control 119 
were obtained from the literature. For GlyA gene, the sequences were: forward: 5’-120 
CCCAATTCACCAACAAATATGC-3’, and reverse: 5’-ATTCTTTCGCACGCTCAATAG-3’ (Isaza et al. 121 
2008). For LtxA gene the sequences were: forward: 5’-GTGCTAGGTAAACATCGGTAAAG-3’, and 122 
reverse 5’-GACCACAGAGGCAATTAACC-3’ (Isaza et al. 2008). Before proceeding to the quantification 123 
reactions, the specificity of each primer pair was evaluated with the melt-curve analysis software of the 124 
Prism7000 Sequence Detection System (Applied Biosystems). The selected primers pairs showed no 125 
unspecific peaks. Calculation of expression values for each gene was performed by the 2-∆Ct method, 126 
calibrated against the expression of GlyA endogenous control that was found to be consistently expressed 127 
under all conditions. Cycle threshold is abbreviated as Ct and the ∆Ct calculation was as follows: Ct (+RT) - 128 
Ct (-RT) = cCt (corrected CT). ∆Ct = cCt (target gene) - cCt (endogenous control gene, GlyA) (Belibasakis et 129 
al. 2011).  130 
 131 
Statistic analysis 132 
Experiments were performed at least three times to ensure reproducibility of results. The results are reported 133 
as means ± standard deviations (SD). A two-way ANOVA followed by Tukey’s test were used for statistical 134 
comparisons, and P < 0.05 was considered statistically significant. 135 
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 136 
Results 137 
The growth of A. actinomycetemcomitans was not inhibited when cultured in the presence of cell-free 138 
lactobacilli culture supernatants, over the 6 h experimental period (Table 1). Nevertheless, the expression of 139 
CdtB and LtxA genes was attenuated in both A. actinomycetemcomitans strains, when cultured in the presence 140 
of lactobacilli cell-free supernatants. Supernatants from both L. salivarius and L. gasseri were capable to 141 
down-regulate CdtB and LtxA gene expressions, but in different manners. 142 
 143 
Relative expression of CdtB subunit 144 
The attenuation of CdtB gene expression of A. actinomycetemcomitans OMZ295 (Figure 1) was evident at 3 145 
h, and mainly when exposed to L. salivarius  supernatant. At this early time-point, L. salivarius significantly 146 
down-regulated CdtB expression by more than 4-fold compared to the control. On the other hand, L. gasseri 147 
was slightly less potent in this effect, by causing a less than 3-fold down-regulation, in comparison to the 148 
respective control. This attenuation of CdtB expression was maintained over 6 h in the presence of L. 149 
salivarius, but partly resumed the levels of the untreated A. actinomycetemcomitans control in the presence of 150 
L. gasseri. In the case of A. actinomycetemcomitans strain OMZ250b, both L. gasseri and L. salivarius 151 
supernatants inhibited CdtB expression as early as 3 h, by approximately 3-fold compared to the control 152 
(Figure 1). After 6 h, the attenuation of CdtB expression was persistent in the presence of either L. salivarius 153 
or L. gasseri, which was in both cases more than 2-fold lower compared to the control. 154 
 155 
Relative expression of the LtxA subunit 156 
The expression of LtxA was further investigated. In the case of A. actinomycetemcomitans strain OMZ295, 157 
LtxA expression was reduced already at 3 h in the presence of L. salivarius, compared to the untreated 158 
control, and this attenuation was maintained over 6 h (Figure 2). On the contrary, in the presence of L. 159 
gasseri, LtxA expression was not significantly affected after 3 h, but at 6 h this was significantly down-160 
regulated compared to the control, and to a similar extent as in the case of L. salivarius (Figure 2). The effect 161 
of lactobacilli supernatants on LtxA expression was also investigated in A. actinomycetemcomitans strain 162 
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OMZ250b. LtxA expression in this strain was significantly down-regulated in the presence of either 163 
lactobacilli species already after 3 h, and this effect persisted over 6 h (Figure 2). L. gasseri was more potent 164 
than L. salivarius in attenuating LtxA expression, particularly after 3 h of A. actinomycetemcomitans 165 
OMZ250b culture. 166 
 167 
Discussion 168 
The ability of lactobacilli and other lactic acid bacteria (LAB) to colonize the oral cavity and in particular the 169 
periodontium is still debated. Some lactobacilli are indigenous and inhabit the oral cavity of the newborn as 170 
they are transferred from the mother (e.g. Lactobacillus vaginalis and the bifidobacteria group). This 171 
phenomenon is not restricted to the oral cavity, but is generalized to the whole human body. As it happens for 172 
the GIT, the skin and for several mucosas, the first bacteria to settle and colonize these niches are mainly 173 
bifidobacteria, but even lactobacilli and other LAB species. Most of these are considered probiotic, or at least 174 
not harmful, commensals. This study aimed to identify if oral lactobacilli, with proven probiotic capability in 175 
the GIT, are able to attenuate or inhibit the gene expression of the two major exotoxins (virulence factors) of 176 
the putative periodontal pathogen A. actinomycetemcomitans. The selection of L. salivarius and L. gasseri as 177 
putative oral probiotics, was justified by their detection in the composition of the microbiota of the 178 
periodontium; primarily at healthy sites, compared to sites affected by periodontitis (Koll-Klais et al. 2005; 179 
Hojo et al. 2007; Badet and Thebaud. 2008; Pham et al. 2009). Concerning L. salivarius there are reports 180 
proposing that this species could act as putative probiotic for the periodontium (Shimauchi et al. 2008; 181 
Mayanagi et al. 2009; Iwamoto et al. 2010). Up to date, considering the limited number of papers dealing with 182 
this issue, L. salivarius is perhaps the best characterized indigenous putative probiotic species inhabiting the 183 
oral cavity. While some authors have reviewed and supported the health benefits of probiotics in the oral 184 
cavity (Meurman and Stamatova. 2007; Stamatova and Meurman. 2009), it is interest to mention that some 185 
studies have described lactobacilli (Mantzourani et al. 2009a; Mantzourani et al. 2009b), and in particular L. 186 
salivarius in association with caries (Matsumoto et al. 2005). Another study has shown in an in vitro model 187 
that L. salivarius decreased the numbers of black pigmented anaerobic rods that are associated with 188 
periodontitis (Ishikawa et al. 2003). Notwithstanding, there are no studies on the molecular cross-talk between 189 
  9
lactobacilli or their products on the virulence mechanisms of putative oral pathogens. Lactobacillus gasseri 190 
was selected for the present experimental system mainly based on recent findings that outlined this species as 191 
one of the most potent among a set of new isolates of putative probiotic/beneficial bacteria (Nissen et al. 192 
2009; Kawase et al. 2011). Considering all these aspects, to our knowledge the present study is one of the first 193 
that has addressed the effects of lactobacilli on the expression of virulence factors of any putative oral 194 
pathogen. Both lactobacilli species tested in this study, demonstrated promising results in competition with 195 
putative periodontal pathogen A. actinomycetemcomitans. The attenuation of gene expression of the two 196 
toxins appears to be visible as early as 3 h, and is not commensurate with a reduction of A. 197 
actinomycetemcomitans growth. The effect on LtxA expression appeared to be more time-dependent than that 198 
on CdtB expression. The present results also demonstrate that both of the tested A. actinomycetemcomitans 199 
strains, namely OMZ250b (which is a Y4 clone) and OMZ295 (which is a JP2 clone), are sensitive to the 200 
presence of lactobacilli supernatants, even though the JP2 clone generally exhibits higher toxin activity than 201 
the Y4 clone (Kawamoto et al. 2009).  202 
The ecological complexity of the oral cavity environment is partly attributed to interrelationships between 203 
different species (i.e. synergistic or antagonistic), that is subject to changes due to food intake and diet habits. 204 
Indeed, the oral microbiome is in constant exposure to the products of the cud, which can directly affect its 205 
ecology. In this complex environment, an equilibrium ratio of beneficial and pathogenic microbes is essential: 206 
to prevent the establishment of dental caries or periodontal diseases, and to potentially reduce the emanation 207 
of bacterial toxins further distally into the GIT. The mechanism by which the cell free supernatants of the 208 
lactobacilli tested are able to affect mRNA expression of A. actinomycetemcomitans virulence factors is 209 
unknown. Nevertheless, the present findings that lactobacilli at densities as low as 104 CFU/ml can elicit an 210 
adequate effect on reducing the expressions of leukotoxin and Cdt is encouraging, since it demonstrates that a 211 
high probiotic load is not necessary for potential therapies. It is otherwise, well documented that LAB species 212 
are able to produce a class of molecules with antimicrobial capability. For instance, bacteriocins produced by 213 
L. gasseri are able to inhibit enteric pathogens (Itoh et al. 1995;  Alpay Karaoglu et al. 2003). Moreover, 214 
bacteriocins produced by L. salivarius are able to inhibit the growth of clinical Staphylococcus aureus isolates 215 
(Robredo and Torres. 2000), as well as Listeria monocytogenens (Corr et al. 2007). The effect of this class of 216 
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molecules and other antimicrobial factors produced by lactobacilli is inhibitory against bacterial pathogens at 217 
a certain dosage, but the effect of minimal doses remains unclear. Recently, it was reported that sub-lethal 218 
dosage of different antimicrobials could down-regulate the expression of virulence genes of bacterial 219 
pathogens, such as Vibrio cholerae (Chatterjee et al. 2010; Yamasaki et al. 2011) and Staphylococcus aureus 220 
(Smith-Palmer et al. 2004; Qiu et al. 2011), without inhibiting its growth. This action could reflect the effects 221 
observed in the present work in A. actinomycetemcomitans.  222 
The results obtained in this study indicate that probiotic species (i.e. lactobacilli) may reduce the virulence 223 
capacities of putative oral pathogens, at least as judged by the effects on A. actinomycetemcomitans. This 224 
observation could be useful to produce an application able to control or eradicate the presence of putative 225 
periodontal pathogens in the periodontium. The possibility to manage oral diseases with a natural, non 226 
invasive and non stressful method is particularly appealing, and may prevent problems related to 227 
pharmacological treatments, such as the use of antibiotics. Last, but not least, the use of cell free supernatants 228 
instead of viable bacteria is an added value for wider and easier application, particularly for these diseases 229 
embracing the immune system, in order to prevent the continuous antigenic load. 230 
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 337 
Table 1. Growth of A. actinomycetemcomitans strain OMZ250b and OMZ295 for up 345 to 6 h in the 338 
presence of lactobacilli cell-free culture supernatants. 339 
Strain        Bacterial growth at OD600 340 
Time (h) 341 
0 h*   3 h   6 h 342 
A. actinomycetemcomitans OMZ 250b alone  0.4   0.455 ± 0.035  0.77 ± 0.028 343 
+ L. salivarius OMZ 520    0.4   0.45 ± 0.014  0.645 ± 0.007 344 
  15
+ L. gasseri OMZ 525    0.4   0.435 ± 0.021  0.67 ± 0.084 345 
A. actinomycetemcomitans OMZ 295 alone   0.4   0.46 ± 0.014  0.665 ± 0.022 346 
+ L. salivarius OMZ 520   0.4   0.45 ± 0.015  0.615 ± 0.014 347 
+ L. gasseri OMZ 525    0.4   0.44 ± 0.007  0.525 ± 0.049 348 
*starting bacterial inoculum. 349 
 350 
Figure Captions 351 
Fig. 1 Effect of lactobacilli cell-free culture supernatants on CdtB expression in A. actinomycetemcominats 352 
OMZ295 and OMZ250b, measured by qRT-PCR. *Statistically significant difference (P < 0.05), compared to 353 
the untreated A. actinomycetemcomitans OMZ295 control, at the corresponding time-point. **Statistically 354 
significant difference (P < 0.05), compared to the untreated A. actinomycetemcomitans OMZ250b control, at 355 
the corresponding time-point. 356 
 357 
Fig. 2 Effect of lactobacilli cell-free culture supernatants on LtxA expression in A. actinomycetemcominats 358 
OMZ295 and OMZ250b, measured by qRT-PCR. *Statistically significant difference (P < 0.05), compared to 359 
the untreated A. actinomycetemcomitans OMZ295 control, at the corresponding time-point. **Statistically 360 
significant difference (P < 0.05), compared to the untreated A. actinomycetemcomitans OMZ250b control, at 361 
the corresponding time-point. 362 
 363 
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